Effect of Nisoldipine and Olmesartan on Endothelium-Dependent Vasodilation in Essential Hypertensive Patients

CNS Neuroscience and Therapeutics

Volumn 18, Issue 5, 2012, Pages 400-405

  Wei, Duo ^a   He, Wan Yuan ^a   Lv, Qian Zhou ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Endothelin; Nisoldipine; Olmesartan; Vasodilation

Indexed keywords

8 ISOPROSTANE; C REACTIVE PROTEIN; ENDOTHELIN; HYDROCHLOROTHIAZIDE; N(G),N(G) DIMETHYLARGININE; NISOLDIPINE; NITRIC OXIDE; OLMESARTAN; PROSTAGLANDIN F2 ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFECT; ENDOTHELIUM; ESSENTIAL HYPERTENSION; FEMALE; FLOW MEDIATED DILATATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASODILATATION;

AGED; ANILINE COMPOUNDS; ANTHRACENES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENDOTHELIN-1; ENDOTHELIUM; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; NISOLDIPINE; NITRIC OXIDE; PROPANE; PROSTAGLANDINS F; SINGLE-BLIND METHOD; TETRAZOLES; VASODILATION;

EID: 84860300661     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00304.x     Document Type: Article

References (40)

1. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007;22:316-320.
2. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary artery disease. Circulation 2000;101:1899-1906.
3. Roquer J, Segura T, Serena J, Castillo J. Endothelial dysfunction, vascular disease and stroke: The ARTICO Study. Cerebrovasc Dis 2009;27:25-37.
4. Fang XH, Zhang XH, Yang QD, et al. Subtype hypertension and risk of stroke in middle-aged and older Chinese: A 10-year follow-up study. Stroke 2006;37:38-43.
5. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. Circulation 1993;87:1468-1474.
6. Shiekh GA, Ayub T, Khan SN, Dar R, Andrabi KI. Reduced nitrate level in individuals with hypertension and diabetes. J Cardiovasc Dis Res 2011;2:172-176.
7. Feletou M, Vanhoutte PM. Endothelial dysfunction: A multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006;291:H985-1002.
8. Böhm F, Ahlborg G, Pernow J. Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: Reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (Lond) 2002;102:321-327.
9. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000;87:840-844.
10. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine(ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010;6:82-90.
11. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-1441.
12. Benndorf RA, Gehling UM, Appel D, et al. Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension. Stem Cells Dev 2007;16:329-338.
13. Berkels R, Roesen R, Bartels H, et al. Nisoldipine increases the bioavailability of endothelial NO. Naunyn-Schmiedeberg's Arch Pharmacol 2001;364:110-116.
14. Liu JJ, Casley D, Wojta J, et al. Reduction of endothelin levels by the dihydropyridine calcium antagonist nisoldipine and a 'natural factor' in cultured human endothelial cells. J Hypertens 1993;11:977-982.
15. Rosenkranz AC, Lob H, Breitenbach T, Berkels R, Roesen R. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol 2006;529:55-62.
16. Naya M, Tsukamoto T, Morita K, et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-1149.
17. Takiguchi S, Ayaori M, Uto-Kondo H, et al. Olmesartan improves endothelial function in hypertensive patients: Link with extracellular superoxide dismutase. Hypertens Res 2011;34:686-692.
18. Gao X, Hofman A, Hu Y, et al. The Shanghai Changfeng Study: A community-based prospective cohort study of chronic diseases among middle-aged and elderly: Objectives and design. Eur J Epidemiol 2010;25:885-893.
19. Whitworth JA. World Health Organization International Society of Hypertension Guideline for the management of Hypertension. J Hypertens 2003;21:1983-1992.
20. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
21. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) sing a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-1383.
22. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial dysfunction in hypertension. Fact or fancy? J Cardiovasc Pharmacol 1998;32(Suppl. 3):S41-S47.
23. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: Methods of assessment and application to hypertension. Curr Pharm Des 2004;10:3591-3605.
24. Ohnishi M, Wada A, Tsutamoto T, et al. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci (Lond) 2002;103(Suppl. 48):241S-244S.
25. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:367-371.
26. Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006;29:567-572.
27. Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: A meta-analysis of randomized controlled trials. Atherosclerosis 2011;216:7-16.
28. Hong HJ, Chan P, Liu JC, et al. Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells. Cardiovasc Res 2004;61:159-168.
29. Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008;49:681-689.
30. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa k. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008;30:267-276.
31. Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens 2010;32:121-128.
32. Ishida S, Koto T, Nagai N, Oike Y. Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. Jpn J Ophthalmol 2010;54:594-601.
33. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension. J Hypertens 2001;9:857-861.
34. Wu SL, Gao JS, Hao B, et al. Serum C-reactive protein level is associated with essential hypertension. Chin J Cardiol 2003;31:917-920.
35. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura k. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003;42:985-990.
36. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518-523.
37. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008;21:1251-1257.
38. Bellien J, Thuillez C, Joannides R. Contribution of endothelium-derived hyperpolarizing factors to the regulation of vascular tone in humans. Fundam Clin Pharmacol 2008;22:363-377.
39. Sun D, Huang A, Smith CJ, et al. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilatation in eNOS knockout mice. Circ Res 1999;85:288-293.
40. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003;60:191-196.